论文部分内容阅读
目的:观察长春瑞滨联合顺铂同步放疗与单纯放疗对老年晚期非小细胞肺癌的疗效与安全性。方法:晚期非小细胞肺癌患者47例,随机分为治疗组(27例)和对照组(20例)。治疗组给予长春瑞滨联合顺铂方案化疗和同步放疗,放疗总剂量60Gy,对照组给予单纯放疗。用WHO标准评价疗效。结果:治疗组和对照组客观缓解率分别为74%(20/27)和45%(9/20),2组比较差异有统计学意义(P<0.05);中位生存期分别为14.5个月和11.5个月,1年生存率分别为52%和40%,2年生存率分别为28%和15%,2组患者发生不同程度的放射性食管炎,白细胞减少,放射性肺损伤。结论:长春瑞滨联合顺铂同步放疗治疗晚期非小细胞肺癌疗效满意。
Objective: To observe the curative effect and safety of vinorelbine plus cisplatin combined with concurrent radiotherapy and radiotherapy alone in elderly patients with advanced non-small cell lung cancer. Methods: Forty-seven patients with advanced non-small cell lung cancer were randomly divided into treatment group (n = 27) and control group (n = 20). Treatment group was given vinorelbine combined with cisplatin chemotherapy and concurrent radiotherapy, the total dose of 60 Gy of radiotherapy, the control group was given radiotherapy alone. Evaluation of the efficacy of WHO standards. Results: The objective response rates were 74% (20/27) and 45% (9/20) respectively in the treatment group and the control group, with significant difference between the two groups (P <0.05). The median survival time was 14.5 Month and 11.5 months, respectively. The 1-year survival rates were 52% and 40% respectively, and the 2-year survival rates were 28% and 15% respectively. Radiation esophagitis, leukopenia and radiation-induced lung injury were observed in 2 groups. Conclusion: Vinorelbine combined with cisplatin concurrent radiotherapy for advanced non-small cell lung cancer is satisfactory.